ARAY (Accuray) Short-Term Debt: $11.2 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARAY Accuray Inc ARAY
44 GF Score
Price $0.27
GF Value $1.34
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Accuray Short-Term Debt?

Accuray ARAY -3.05% 44 Short-Term Debt is $11.2 Mil as of Mar. 2026. GuruFocus rates ARAY with a GF Score™ of 44/100 and a GF Value™ of $1.34 (Possible Value Trap). The stock has 6 warning signs investors should review.

Accuray's Short-Term Debt for the quarter that ended in Mar. 2026 was $11.2 Mil.

Accuray's quarterly Short-Term Debt declined from Sep. 2025 ($12.9 Mil) to Dec. 2025 ($11.1 Mil) but then increased from Dec. 2025 ($11.1 Mil) to Mar. 2026 ($11.2 Mil).

Accuray's annual Short-Term Debt increased from Jun. 2023 ($5.7 Mil) to Jun. 2024 ($7.8 Mil) and increased from Jun. 2024 ($7.8 Mil) to Jun. 2025 ($12.7 Mil).

Accuray Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Accuray Short-Term Debt Related Terms

Accuray Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Accuray's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accuray Short-Term Debt Chart

Accuray Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.79 8.56 5.72 7.76 12.73

Accuray Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.57 12.73 12.85 11.11 11.16
ARAY
44GF Score
Accuray Inc ARAY
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $11.2 Mil mean?
Accuray (ARAY) has a Short-Term Debt of $11.2 Mil as of Mar. 2026.
Is Accuray's Short-Term Debt too high?
Accuray's current Short-Term Debt is $11.2 Mil. Overall, Accuray has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Accuray's Short-Term Debt compare to PETV and NSPR?
Accuray's Short-Term Debt of $11.2 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Accuray's current Short-Term Debt is $11.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accuray stock overvalued right now?
Based on GuruFocus' analysis, Accuray (ARAY) is currently considered Possible Value Trap. The stock's GF Value™ is $1.34, compared to a current price of $0.27 — trading 80% below its estimated fair value. The current Short-Term Debt is $11.2 Mil. Accuray's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Accuray (ARAY), the current Short-Term Debt is $11.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Accuray (ARAY) Overvalued in 2026?

Based on GuruFocus' analysis, Accuray stock appears to be undervalued. The current stock price of $0.27 is trading 80% below its estimated GF Value™ of $1.34. GuruFocus considers Accuray to be Possible Value Trap.

Key valuation signals for ARAY:

  • Short-Term Debt: $11.2 Mil
  • GF Value™: $1.34 vs. price of $0.27 (80% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the ARAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Accuray Business Description

Other Exchanges 0H8I:UKXEJ:Germany
Address 1240 Deming Way, Madison, WI, USA, 53717
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
44GF Score

Get the complete analysis for ARAY

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.27
Price
$1.34
GF Value